Parse Biosciences Wins Patent Invalidation Case Against 10x Genomics in Single Cell Sequencing Dispute
核心洞察
The District Court for the District of Delaware granted Parse Biosciences (搜索)' Motion for Summary Judgment, invalidating Scale Biosciences (搜索)' (now 10x Genomics (搜索)) patent 11,634,752 for lack of written description and enablement.
Parse Biosciences (搜索), which has raised over $100 million in capital and serves over 3,000 customers worldwide, provides accessible single cell sequencing solutions that have enabled discoveries in cancer (搜索) treatment and other therapeutic areas.
The company's technology portfolio includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, and Gene Select platforms for single cell analysis.
Parse Biosciences (搜索) has secured a significant legal victory in the competitive single cell sequencing market, with the District Court for the District of Delaware granting the company's Motion for Summary Judgment of Invalidity against Scale Biosciences (搜索)' patent 11,634,752. The Court concluded that the claims of the '752 patent, held by Scale Biosciences (now part of 10x Genomics (搜索)), were invalid for lack of written description and lack of enablement.
Patent Dispute Resolution
The invalidation of the Scale Biosciences (搜索) patent removes a potential intellectual property barrier for Parse Biosciences (搜索), a Seattle-based company that has positioned itself as a leading provider of accessible and scalable single cell sequencing solutions. The court's decision specifically cited deficiencies in the patent's written description and enablement requirements, fundamental criteria for patent validity.
Company Growth and Market Position
Parse Biosciences (搜索) has demonstrated substantial growth in the single cell sequencing market, having raised over $100 million in capital and currently serving over 3,000 customers worldwide. The company's technology, originally developed at The University of Washington by co-founders Alex Rosenberg and Charles Roco, has enabled researchers to perform single cell sequencing with what the company describes as "unprecedented scale and ease."
Therapeutic Applications and Research Impact
The company's single cell sequencing platforms have contributed to groundbreaking discoveries across multiple therapeutic areas. According to Parse Biosciences (搜索), their technology has enabled advances in cancer (搜索) treatment, tissue repair, stem cell therapy, kidney and liver disease (搜索) research, brain development studies, and immune system analysis.
Technology Portfolio
Parse Biosciences (搜索) has developed a comprehensive portfolio of single cell analysis products, including Evercode Whole Transcriptome for comprehensive gene expression analysis, Evercode TCR and Evercode BCR for immune receptor profiling, CRISPR Detect for functional genomics applications, and Gene Select for targeted analysis. The company also offers Trailmaker, an interactive data analysis solution designed to support researchers in interpreting single cell sequencing data.
Corporate Expansion
The company has recently expanded its operations with a move to new headquarters and a state-of-the-art laboratory facility in Seattle's South Lake Union district, reflecting its continued growth in the life sciences sector. This expansion supports Parse Biosciences (搜索)' mission to accelerate progress in human health and scientific research through improved accessibility to single cell sequencing technologies.